<DOC>
	<DOCNO>NCT01421563</DOCNO>
	<brief_summary>The purpose study compare safety pharmacokinetic characteristic DP-R202 ( Sarpogrelate HCl 300mg , qd ) Anplag ( Sarpogrelate HCl 100mg , tid ) oral administration healthy male volunteer .</brief_summary>
	<brief_title>Safety Pharmacokinetic Characteristics DP-R202 Healthy Male Volunteers</brief_title>
	<detailed_description>The number patient thirthy-six.Patients randomly assign either anplag tablet ( Sarpogrelate HCL 100mg , tid ) first , DP-R202 ( Sarpogrelate HCL 300mg , qd ) Second DP-R202 ( Sarpogrelate HCL 300mg , qd ) first , anplag tablet ( Sarpogrelate HCL 100mg , tid ) second .</detailed_description>
	<mesh_term>Sarpogrelate</mesh_term>
	<criteria>20 55 year healthy volunteer Hypersensitivity Reaction Sarpogrelate HCL antiplatelets</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>